Environmental

IMRX appears to have limited direct environmental exposure as a biotech, so peer differentiation is driven more by lab operations and supply-chain controls than by emissions intensity.

The provided R&D-to-revenue metric is zero, which limits evidence of environmental efficiency disclosure versus peers that typically report more complete operational intensity metrics.

Low leverage reduces pressure for environmentally driven cost-cutting, but it does not by itself create an environmental advantage over similarly capital-light biotech peers.

No Tier 1 filing evidence was provided on energy use, waste, or hazardous-material management, leaving environmental positioning broadly in line with peers rather than clearly stronger.

Social

As a clinical-stage biotech, IMRX’s social profile is primarily shaped by patient safety, trial ethics, and data integrity, which are material across the peer set.

The absence of disclosed social metrics in the provided data makes it difficult to show stronger workforce or community practices than peers with more detailed reporting.

Biotech peers generally face similar scrutiny on informed consent and adverse-event management, so IMRX is not clearly advantaged on social risk from the available evidence.

Limited disclosure on human-capital practices and trial governance suggests a middle-of-pack social position rather than a structurally superior one.

Governance

IMRX’s very low debt-to-equity ratio of 0.019 suggests a conservative capital structure, which reduces creditor pressure and supports governance flexibility versus leveraged peers.

Net debt to EBITDA of 0.61 is modest, indicating less balance-sheet stress than many development-stage peers and lowering governance risk from refinancing dependence.

The provided zero stock-based-compensation-to-revenue metric does not indicate excessive dilution pressure, but it also offers limited evidence of superior compensation discipline.

Without filing-based detail on board independence, audit controls, or shareholder rights, governance appears acceptable but not clearly stronger than best-in-class biotech peers.

Overall Score

IMRX screens as a mid-pack ESG name versus biotech peers, with its strongest relative feature being conservative leverage and its main limitation being sparse disclosure.

Score Driver: Conservative Balance-Sheet Structure Modestly Strengthens Governance Relative To Peers, But Limited ESG Disclosure Prevents A Stronger Overall Relative Score.